Show simple item record

dc.contributor.authorEgusquiza, Iker
dc.contributor.authorMunarriz Cuezva, Eva
dc.contributor.authorSegarra Echevarria, Rafael
dc.contributor.authorGonzález Maeso, Javier
dc.contributor.authorCallado Hernando, Luis Felipe ORCID
dc.contributor.authorMeana Martínez, José Javier ORCID
dc.contributor.authorDíez Alarcia, Rebeca ORCID
dc.date.accessioned2022-01-07T11:01:56Z
dc.date.available2022-01-07T11:01:56Z
dc.date.issued2021-08
dc.identifier.citationPharmacological Reports 73(4) :1136-1146 (2021) Número especiales_ES
dc.identifier.issn1734-1140
dc.identifier.issn2299-5684
dc.identifier.issn10.1007/s43440-021-00305-4
dc.identifier.urihttp://hdl.handle.net/10810/54834
dc.description.abstractBackground: Alterations of dopamine D-1 (D1R) and D-2 receptor (D2R) are proposed in schizophrenia but brain neuroimaging and postmortem studies have shown controversial results in relation to D1R and D2R density. Besides, scarce information on the functionality of brain D1R and D2R is available. The present study characterized G-protein activation by D1R and D2R agonists in postmortem human brain. Furthermore, D2R functional status was compared between schizophrenia and control subjects. Methods: G-protein receptor coupling was assessed in control caudate nucleus and frontal cortex by [S-35]GTP gamma S-binding stimulation induced by increasing concentrations (10(-10)-10(-3) M) of dopamine, and the selective dopaminergic agonists SKF38393 (D1R) and NPA (D2R). Concentration-response curves to NPA stimulation of [S-35]GTP gamma S binding were analyzed in antipsychotic-free (n = 10) and antipsychotic-treated (n = 7) schizophrenia subjects and matched controls (n = 17). Results: In caudate, [S-35]GTP gamma S-binding responses to agonists were compatible with the existence of functional D2R. In contrast, stimulations in cortex showed responses that did not correspond to D1R or D2R. [S-35]GTP gamma S-binding activation by NPA in caudate displayed biphasic curves with similar profile in schizophrenia (EC50H = 7.94 nM; EC50L = 7.08 mu M) and control (EC50H = 7.24 nM; EC50L = 15.14 mu M) subjects. The presence or absence of antipsychotic medication did not influence the pharmacological parameters. Conclusions: Feasibility of functional evaluation of dopamine receptors in postmortem human brain by conventional [S-35]GTP gamma S-binding assays appears to be restricted to signalling through inhibitory G(i/o) proteins. These findings provide functional information about brain D2R status in subjects with schizophrenia and do not support the existence of D2R supersensitive in this mental disorder.es_ES
dc.description.sponsorshipThis work was supported by the Spanish State Research Agency and EDR Funds (SAF-2017-88126-R to JJM;PID2019-106404RB-100 to LFC), the Basque Government (IT1211/19 to JJM ; ELKARTEK Programme KK-2019/00049 to RD-A), and the National Institutes of Health (R01MH084894 & NIH-R01MH111940 to JG-M).es_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/SAF-2017-88126-Res_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/PID2019-106404RB-100es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectD-2 receptorses_ES
dc.subjectschizophreniaes_ES
dc.subjectG proteines_ES
dc.subjectHuman braines_ES
dc.subject[S-35]GTP gamma Ses_ES
dc.subjectdopaminees_ES
dc.subjectgamma-Ses_ES
dc.subjectbindinges_ES
dc.subjectmediated activationes_ES
dc.subjectrat striatumes_ES
dc.subjectagonistes_ES
dc.subjectassayes_ES
dc.subjectautoradiographyes_ES
dc.subjectpharmacologyes_ES
dc.subjecthaloperidoles_ES
dc.subjectantagonistes_ES
dc.titleCharacterization of dopamine D2 receptor coupling to G proteins in postmortem brain of subjects with schizophreniaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holderThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://link.springer.com/article/10.1007%2Fs43440-021-00305-4es_ES
dc.departamentoesFarmacologíaes_ES
dc.departamentoeuFarmakologiaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Except where otherwise noted, this item's license is described as This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.